Regulations and Regulatory Advocacy
The Centers for Medicare & Medicaid Services is appealing a federal court decision that barred the agency from enforcing in Missouri a 2017 final rule and earlier guidance.
The CMS on April 6 finalized a rule that will update the Medicare Advantage and Part D prescription drug programs for contract year 2019.
A federal district court judge in Alabama yesterday ruled that the Blue Cross Blue Shield organizations named in multi-district antitrust litigation in that court must defend under a strict per se standard of review the geographic and output restrictions in the 鈥渆xclusive service area鈥 and 鈥溾
CMS anticipates MA plans and Part D sponsors will see an average revenue increase of 3.4%, excluding an expected 3.1% increase in risk scores.
The Centers for Medicare & Medicaid Services today issued a proposed rule that would exempt states with an overall Medicaid managed care penetration rate of 85% or more from most access-to-care monitoring requirements, such as requirements to analyze certain data and monitor access in fee-for-鈥
The Centers for Medicare & Medicaid Services will host a March 20 conference call to answer health care providers鈥 questions about preparing for the new Medicare beneficiary identifier.
The Centers for Medicare & Medicaid Services has clarified its inpatient rehabilitation facility medical review guidelines to confirm that auditors should not deny claims solely because a therapy time threshold, commonly referred to as the 鈥3-hour rule,鈥 was not met.
The Food and Drug Administration yesterday alerted health care professionals and patients not to use drug products produced by Cantrell Drug Co., including opioid products and other drugs intended for sterile injection, citing serious deficiencies in the company鈥檚 compounding operations.